A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body.

Rogers Communications Inc. Cl A-1.67% $21.72B Rogers Communications Inc. Cl B 1.11% $21.72B ...

NPR's weekly news quiz hosted by Peter Sagal. Have a laugh and test your knowledge with today's funniest comedians and a celebrity guest.

Huber won't hold a large position in a stock simply because of its yield, though. In times of heightened uncertainty, Huber emphasizes nonyield characteristics, including valuation, balance-sheet ...